Astra, Daiichi said to be nearing U.K. drug pricing deal for breast cancer drug, Enhertu
Seeking Alpha ·
AstraZeneca ( AZN ) and Daiichi Sankyo ( DSNKY ) are closing in on a pricing deal with England’s health spending watchdog to offer their breast cancer therapy. Enhertu, across the country's National Health Service, Bloomberg News reported on Wednesday.
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
376 participants
Related News
- Prime Medicine gains after winning arbitration with Beam Therapeutics
- Oil rebound gathers pace as shorts crowd into crude market
- Laser Photonics secures first REXA order for CleanTech laser system
- TSMC expected to increase guidance, capex at Q2 analyst meeting: GF Securities
- BioStem Technologies gains four U.S. design patents for placental allograft technology
- Why JPMorgan’s (JPM) Dividend Hike and $50 Billion Buyback Make It a Strong Capital-Return Tax Case